Diabetic Kidney Disease Pipeline 2025: Key Companies, MOA, ROA, And Clinical Trials Evaluation By Delveinsight Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa Kirin

(MENAFN- GetNews)

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Diabetic Kidney Disease pipeline constitutes key companies continuously working towards developing Diabetic Kidney Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Diabetic Kidney Disease Pipeline Insight, 2025 " report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Kidney Disease Market.

The Diabetic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Diabetic Kidney Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Diabetic Kidney Disease treatment therapies with a considerable amount of success over the years.

• Diabetic Kidney Disease companies working in the treatment market are Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others, are developing therapies for the Diabetic Kidney Disease treatment

• Emerging Diabetic Kidney Disease therapies in the different phases of clinical trials are - ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others a re expected to have a significant impact on the Diabetic Kidney Disease market in the coming years.

• In April 2025, A recent study led by Sankar D. Navaneethan and colleagues, published in the International Society of Nephrology, demonstrated that the cardiovascular and kidney benefits of Bayer's Kerendia (finerenone) remain consistent, regardless of initial acute changes in estimated glomerular filtration rate (eGFR) after starting treatment in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

• In November 2024, At the American Heart Association (AHA) conference, during a key session titled "GLP-1RAs and Beyond: Incretin Analogues and a New Frontier in Cardiovascular Therapeutics," Dr. Katherine Tuttle explored the renal benefits of glucagon-like peptide-1 (GLP-1) receptor agonist therapy. She specifically highlighted Novo Nordisk's Ozempic (semaglutide), emphasizing its role in advancing GLP-1 treatments for managing diabetic kidney disease.

• In March 2024, Hua Medicine, based in China, intends to prioritize the development of its type 2 diabetes (T2D) medication for diabetic kidney patients in the United States. According to George Lin, the Chief Strategy Officer, the company aims to initiate clinical trials specifically tailored for the US market, focusing on creating a once-daily formulation of their drug Huatangning (dorzagliatin).

Diabetic Kidney Disease Overview

Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a complication of diabetes characterized by damage to the kidneys' filtering units, known as nephrons. It is a common complication of both type 1 and type 2 diabetes. Over time, high levels of blood sugar can damage the blood vessels and filtration system in the kidneys, leading to impaired kidney function.

Get a Free Sample PDF Report to know more about Diabetic Kidney Disease Pipeline Therapeutic Assessment-

Emerging Diabetic Kidney Disease Drugs Under Different Phases of Clinical Development Include:

• ORBCEL-M: Orbsen Therapeutics

• DMX-200: Dimerix Bioscience

• INV-202: Inversago Pharma

• CSL346: CSL Behring

• Bardoxolone methyl: Kyowa kirin

Diabetic Kidney Disease Pipeline Therapeutics Assessment

• Diabetic Kidney Disease Assessment by Product Type

• Diabetic Kidney Disease By Stage and Product Type

• Diabetic Kidney Disease Assessment by Route of Administration

• Diabetic Kidney Disease By Stage and Route of Administration

• Diabetic Kidney Disease Assessment by Molecule Type

• Diabetic Kidney Disease by Stage and Molecule Type

DelveInsight's Diabetic Kidney Disease Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Diabetic Kidney Disease product details are provided in the report. Download the Diabetic Kidney Disease pipeline report to learn more about the emerging Diabetic Kidney Disease therapies

Some of the key companies in the Diabetic Kidney Disease Therapeutics Market include:

Key companies developing therapies for Diabetic Kidney Disease are - AstraZeneca, Pfizer Inc., Novartis AG, Bayer AG, Sanofi Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Sun Pharmaceutical, and others.

Diabetic Kidney Disease Pipeline Analysis:

The Diabetic Kidney Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Kidney Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Kidney Disease Treatment.

• Diabetic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Diabetic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Kidney Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diabetic Kidney Disease drugs and therapies

Diabetic Kidney Disease Pipeline Market Drivers

• Increasing prevalence of diabetes worldwide, rising geriatric population, increasing demand of novel therapies are some of the important factors that are fueling the Diabetic Kidney Disease Market.

Diabetic Kidney Disease Pipeline Market Barriers

• However, lack of skilled professionals to treat diabetic kidney disease in less developed countries, stringent regulatory guidelines and other factors are creating obstacles in the Diabetic Kidney Disease Market growth.

Scope of Diabetic Kidney Disease Pipeline Drug Insight

• Coverage: Global

• Key Diabetic Kidney Disease Companies: Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, and others

• Key Diabetic Kidney Disease Therapies: ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, and others

• Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies

• Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers

Request for Sample PDF Report for Diabetic Kidney Disease Pipeline Assessment and clinical trials

Table of Contents

1. Diabetic Kidney Disease Report Introduction

2. Diabetic Kidney Disease Executive Summary

3. Diabetic Kidney Disease Overview

4. Diabetic Kidney Disease- Analytical Perspective In-depth Commercial Assessment

5. Diabetic Kidney Disease Pipeline Therapeutics

6. Diabetic Kidney Disease Late Stage Products (Phase II/III)

7. Diabetic Kidney Disease Mid Stage Products (Phase II)

8. Diabetic Kidney Disease Early Stage Products (Phase I)

9. Diabetic Kidney Disease Preclinical Stage Products

10. Diabetic Kidney Disease Therapeutics Assessment

11. Diabetic Kidney Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diabetic Kidney Disease Key Companies

14. Diabetic Kidney Disease Key Products

15. Diabetic Kidney Disease Unmet Needs

16 . Diabetic Kidney Disease Market Drivers and Barriers

17. Diabetic Kidney Disease Future Perspectives and Conclusion

18. Diabetic Kidney Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

MENAFN14072025003238003268ID1109798099